Breast Cancer
Latest News
Advertisement
Latest Videos
CME Content
Advertisement
More News
The PREFERABLE-EFFECT study found that supervised resistance and aerobic exercise were associated with reduced fatigue in patients with metastatic breast cancer.
Data from the DESTINY-Breast06 trial support the FDA breakthrough therapy designation for T-DXd in HR–positive, HER2-low, or HER2-ultralow breast cancer.
11 Phase 3 Study of Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy, Followed by Adjuvant Pembrolizumab or Placebo Plus Endocrine Therapy for Early-Stage High-Risk ER+/HER2– Breast Cancer: KEYNOTE-756
ByFatima Cardoso,Joyce O’Shaughnessy, MD,Heather McArthur, MD, MPH,Peter Schmid, MD,Javier Cortés, MD,Nadia Harbeck, MD, PhD,Melinda L. Telli, MD,David W. Cescon,Peter A. Fasching,Zhimin Shao,Delphine Loirat,Yeon Hee Park,Manuel Gonzalez Fernandez,Gábor Rubovszky,Seock-Ah Im,Rina Hui,Toshimi Takano,Fabrice André,Hiroyuki Yasojima,Zhenzhen Liu,Yu Ding,Liyi Jia,Vassiliki Karantza,Konstantinos Tryfonidis,Aditya Bardia, MD, MPH, FASCO
Phase 1 AC699-001 results evaluating the safety and efficacy of AC699 in patients with breast cancer subtypes support the Fast Track designation.
Findings from a population-based study suggest patients with POI may need genetic counseling regarding future risk of reproductive cancers.
Neoadjuvant/adjuvant sacituzumab govitecan showed encouraging intratumoral concentrations in patients with brain metastases as well as glioblastoma.
16 Open-Label, Randomized, Multicenter, Phase 3, ELAINE 3 Study of the Efficacy and Safety of Lasofoxifene Plus Abemaciclib for Treating ER+/HER2–, Locally Advanced or Metastatic Breast Cancer With an ESR1 Mutation
ByMatthew P. Goetz, MD,Seth A. Wander,Thomas Bachelot,Gerald Batist,Javier Cortés, MD,Massimo Cristofanilli, MD,Giuseppe Curigliano,Alexandre de Nonneville,Einav Nili Gal-Yam,Komal Jhaveri,Cynthia X. Ma, MD, PhD,Heather A. Parsons, MD, MPH,Hope S. Rugo, MD,Sarah L. Sammons,Daniel G. Stover,Chris Twelves, MD, FRCP,Aditya Bardia, MD, MPH, FASCO,Paul V. Plourde,David J. Portman,Senthil Damodaran
NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Retrospective analysis found that cryoablation was associated with infrequent AEs and low recurrence rates among patients with breast cancer.
21 Ribociclib (RIB) + Nonsteroidal Aromatase Inhibitor (NSAI) as Adjuvant Treatment in Patients (pts) With HR+/HER2– Early Breast Cancer (EBC): Final Invasive Disease-Free Survival (iDFS) Analysis From the NATALEE Trial
ByGabriel N. Hortobagyi, MD, FACP,Daniil Stroyakovskiy,Denise A. Yardley, MD,Chiun-Sheng Huang,Peter A. Fasching,John Crown,Aditya Bardia, MD, MPH, FASCO,Stephen Chia,Seock-Ah Im,Miguel Martin, MD, PhD,Sherene Loi, MD, PhD,Binghe Xu,Sara A. Hurvitz, MD,Carlos Barrios,Michael Untch, MD, PhD,Rebecca Moroose,Frances Visco,Federico Parnizari,Farhat Ghaznawi,Zheng Li,Sorcha Waters,Arunava Chakravartty,Dennis J. Slamon, MD, PhD
A holistic integration of time series and static data present in the learning approach can lead to improved understanding of breast cancer outcomes.
Advertisement
Advertisement
Trending on CancerNetwork
1
Modifiable Risk Factors Suggest Potential for Improving Cancer Prevention
2
Dato-DXd Receives Priority Review in Unresectable/Metastatic TNBC
3
2026 Tandem Meetings: What’s the Latest Research in Multiple Myeloma?
4
Outlining Advances in AI For Breast Cancer Screening/Radiomics
5